{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T09:17:05Z","timestamp":1760347025365,"version":"3.37.3"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,14]],"date-time":"2021-07-14T00:00:00Z","timestamp":1626220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,14]],"date-time":"2021-07-14T00:00:00Z","timestamp":1626220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Primary malignant melanoma of the esophagus is a rare form of mucosal melanoma with a poor prognosis. While immune checkpoint inhibitors have recently extended overall survival in metastatic melanoma, data on their effects on primary malignant melanoma\u00a0of the esophagus are limited because of its rarity. Here, we report the first case of long-term complete remission of metastatic primary malignant melanoma\u00a0of the esophagus after nivolumab monotherapy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>A 79-year-old Asian man with a history of prostate cancer, gallbladder cancer, deep vein thrombosis, hypertension, and diabetes mellitus presented with gross hematuria. Cystoscopy revealed a solitary tumor on the right posterior wall of the bladder, and transurethral resection of bladder tumor was performed. Pathology was consistent with metastatic melanoma. A pigmented submucosal tumor-like growth in the esophagus was discovered on esophagogastroduodenoscopy. Computed tomography showed widespread metastases. The patient was diagnosed as having primary malignant melanoma of the esophagus\u00a0with metastases to the stomach, subcutaneous tissue, lung, bladder, pleura, and peritoneum. Complete remission was achieved after seven cycles of triweekly nivolumab monotherapy. While nivolumab was discontinued because of kidney injury, the patient has remained tumor-free for over 4\u00a0years without further treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Immune checkpoint inhibitors may have astonishing curative effects in selected populations. More research is warranted to identify factors that increase the likelihood of achieving complete remission in primary malignant melanoma of the esophagus\u00a0as well as in other melanomas.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13256-021-02928-w","type":"journal-article","created":{"date-parts":[[2021,7,13]],"date-time":"2021-07-13T23:06:32Z","timestamp":1626217592000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Complete remission in metastatic primary malignant melanoma of the esophagus with nivolumab: a case report"],"prefix":"10.1186","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9719-0282","authenticated-orcid":false,"given":"Takeshi","family":"Okamoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eriko","family":"Nakano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teruo","family":"Yamauchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,7,14]]},"reference":[{"key":"2928_CR1","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1001\/archotol.1987.01860100064023","volume":"113","author":"TK Trap","year":"1987","unstructured":"Trap TK, Fu Y, Calcaterra TC. Melanoma of the nasal and paranasal sinus mucosa. Arch Otolaryngol. 1987;113:1086\u20139.","journal-title":"Arch Otolaryngol"},{"key":"2928_CR2","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1046\/j.1365-2273.1998.00099.x","volume":"23","author":"V Nandapalan","year":"1998","unstructured":"Nandapalan V, Roland NJ, Helliwell TR, Williams EM, Hamilton JW, Jones AS. Mucosal melanoma of the head and neck. Clin Otolaryngol Allied Sci. 1998;23:107\u201316.","journal-title":"Clin Otolaryngol Allied Sci"},{"key":"2928_CR3","first-page":"73","volume":"3","author":"H Suzuki","year":"1980","unstructured":"Suzuki H, Nagayo T. Primary tumors of the esophagus other than squamous cell carcinoma. Histologic classification and statistics in the surgical and autopsied materials in Japan. Int Adv Surg Oncol. 1980;3:73\u2013109.","journal-title":"Int Adv Surg Oncol"},{"key":"2928_CR4","first-page":"1475","volume":"84","author":"S Sabanathan","year":"1989","unstructured":"Sabanathan S, Eng J, Pradhan GN. Primary malignant melanoma of the esophagus. Am J Gastroenterol. 1989;84:1475\u201381.","journal-title":"Am J Gastroenterol"},{"key":"2928_CR5","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1080\/07357900701781762","volume":"26","author":"MR Hussein","year":"2008","unstructured":"Hussein MR. Extracutaneous malignant melanomas. Cancer Invest. 2008;26:516\u201334.","journal-title":"Cancer Invest"},{"key":"2928_CR6","doi-asserted-by":"publisher","first-page":"83","DOI":"10.3109\/14017439009101830","volume":"24","author":"S Sabanathan","year":"1990","unstructured":"Sabanathan S, Eng J. Primary malignant melanoma of the esophagus. Scand J Thorac Cardiovasc Surg. 1990;24:83\u20135.","journal-title":"Scand J Thorac Cardiovasc Surg"},{"key":"2928_CR7","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1097\/PAP.0b013e318216b99b","volume":"18","author":"M Bisceglia","year":"2011","unstructured":"Bisceglia M, Perri F, Tucci A, et\u00a0al. Primary malignant melanoma of the esophagus: a clinicopathologic study of a case with comprehensive literature review. Adv Anat Pathol. 2011;18:235\u201352.","journal-title":"Adv Anat Pathol"},{"key":"2928_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/1097-0142(195301)6:1<1::AID-CNCR2820060102>3.0.CO;2-C","volume":"6","author":"AC Allen","year":"1953","unstructured":"Allen AC, Spitz S. Malignant melanoma; a clinicopathological analysis of criteria for diagnosis and prognosis. Cancer. 1953;6:1\u201345.","journal-title":"Cancer"},{"key":"2928_CR9","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1111\/j.1365-4632.2006.02717.x","volume":"45","author":"O Stringa","year":"2006","unstructured":"Stringa O, Valdez R, Beguerie JR, et\u00a0al. Primary amelanotic melanoma of the esophagus. Int J Dermatol. 2006;45:1207\u201310.","journal-title":"Int J Dermatol"},{"key":"2928_CR10","first-page":"9087","volume":"15","author":"J Kobayashi","year":"2018","unstructured":"Kobayashi J, Fujimoto D, Murakami M, Hirono Y, Goi T. A report of amelanotic malignant melanoma of the esophagus diagnosed appropriately with novel markers: a case report. Oncol Lett. 2018;15:9087\u201392.","journal-title":"Oncol Lett"},{"key":"2928_CR11","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa1412082","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Long GV, Brady B, et\u00a0al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372:320\u201330.","journal-title":"N Engl J Med"},{"key":"2928_CR12","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(17)31601-X","volume":"390","author":"J Schachter","year":"2017","unstructured":"Schachter J, Ribas A, Long GV, et\u00a0al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet. 2017;390:1853\u201362.","journal-title":"Lancet"},{"key":"2928_CR13","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373:23\u201334.","journal-title":"N Engl J Med"},{"key":"2928_CR14","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1200\/JCO.2020.38.5_suppl.55","volume":"38","author":"PG Corrie","year":"2020","unstructured":"Corrie PG, Chao D, Board R, et\u00a0al. Metastatic melanoma patient outcomes since introduction of immune checkpoint inhibitors in England between 2014 and 2018. J Clin Oncol. 2020;38:55.","journal-title":"J Clin Oncol"},{"key":"2928_CR15","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1038\/labinvest.2017.64","volume":"97","author":"GJ Kaunitz","year":"2017","unstructured":"Kaunitz GJ, Cottrell TR, Lilo M, et\u00a0al. Melanoma subtypes demonstrate distinct PD-L1 expression profiles. Lab Invest. 2017;97:1063\u201371.","journal-title":"Lab Invest"},{"key":"2928_CR16","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1111\/1759-7714.13034","volume":"10","author":"X Wang","year":"2019","unstructured":"Wang X, Kong Y, Chi Z, et\u00a0al. Primary malignant melanoma of the esophagus: a retrospective analysis of clinical features, management, and survival of 76 patients. Thorac Cancer. 2019;10:950\u20136.","journal-title":"Thorac Cancer."},{"key":"2928_CR17","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1186\/s13256-021-02821-6","volume":"15","author":"S Ito","year":"2021","unstructured":"Ito S, Tachimori Y, Terado Y, Sakon R, Narita K, Goto M. Primary malignant melanoma of the esophagus successfully treated with nivolumab: a case report. J Med Case Rep. 2021;15:237.","journal-title":"J Med Case Rep"},{"key":"2928_CR18","doi-asserted-by":"publisher","first-page":"831","DOI":"10.2217\/imt-2018-0011","volume":"10","author":"P Rochefort","year":"2018","unstructured":"Rochefort P, Roussel J, la Fouchardi\u00e8re A, et\u00a0al. Primary malignant melanoma of the esophagus, treated with immunotherapy: a case report. Immunotherapy. 2018;10:831\u20135.","journal-title":"Immunotherapy"},{"key":"2928_CR19","doi-asserted-by":"publisher","first-page":"e4283","DOI":"10.1097\/MD.0000000000004283","volume":"95","author":"K Inadomi","year":"2016","unstructured":"Inadomi K, Kumagai H, Arita S, et\u00a0al. Bi-cytopenia possibly induced by anti-PD-1 antibody for primary malignant melanoma of the esophagus: a case report. Medicine (Baltimore). 2016;95:e4283.","journal-title":"Medicine (Baltimore)"},{"key":"2928_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0047-6374(99)00010-X","volume":"108","author":"G Pawelec","year":"1999","unstructured":"Pawelec G. Immunosenescence: impact in the young as well as the old? Mech Ageing Dev. 1999;108:1\u20137.","journal-title":"Mech Ageing Dev"},{"key":"2928_CR21","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.jgo.2019.05.013","volume":"11","author":"L Kasherman","year":"2020","unstructured":"Kasherman L, Siu DHW, Lee KWC, et\u00a0al. Efficacy of immune checkpoint inhibitors in older adults with advanced stage cancers: a meta-analysis. J Geriatr Oncol. 2020;11:508\u201314.","journal-title":"J Geriatr Oncol."},{"key":"2928_CR22","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.ctrv.2016.02.006","volume":"45","author":"TF Nishijima","year":"2016","unstructured":"Nishijima TF, Muss HB, Shachar SS, Moschos SJ. Comparison of efficacy of immune checkpoint inhibitors (ICIs) between younger and older patients: a systematic review and meta-analysis. Cancer Treat Rev. 2016;45:30\u20137.","journal-title":"Cancer Treat Rev"},{"key":"2928_CR23","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.ejca.2019.08.027","volume":"121","author":"P Corbaux","year":"2019","unstructured":"Corbaux P, Maillet D, Boespflug A, et\u00a0al. Older and younger patients treated with immune checkpoint inhibitors have similar outcomes in real-life setting. Eur J Cancer. 2019;121:192\u2013201.","journal-title":"Eur J Cancer"},{"key":"2928_CR24","doi-asserted-by":"publisher","DOI":"10.7812\/TPP\/19.093","author":"K Joshi","year":"2020","unstructured":"Joshi K, Atwal D, Ravilla R, et\u00a0al. Immunotherapy outcomes in advanced melanoma in relation to age. Perm J. 2020. https:\/\/doi.org\/10.7812\/TPP\/19.093.","journal-title":"Perm J."},{"key":"2928_CR25","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1634\/theoncologist.2016-0450","volume":"22","author":"AS Betof","year":"2017","unstructured":"Betof AS, Nipp RD, Giobbie-Hurder A, et\u00a0al. Impact of age on outcomes with immunotherapy for patients with melanoma. Oncologist. 2017;22:963\u201371.","journal-title":"Oncologist"},{"key":"2928_CR26","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.jgo.2019.07.005","volume":"11","author":"WJ Archibald","year":"2020","unstructured":"Archibald WJ, Victor AI, Strawderman MS, Maggiore RJ. Immune checkpoint inhibitors in older adults with melanoma or cutaneous malignancies: the Wilmot Cancer Institute experience. J Geriatr Oncol. 2020;11:496\u2013502.","journal-title":"J Geriatr Oncol."},{"key":"2928_CR27","doi-asserted-by":"publisher","first-page":"5347","DOI":"10.1158\/1078-0432.CCR-18-1116","volume":"24","author":"CH Kugel 3rd","year":"2018","unstructured":"Kugel CH 3rd, Douglass SM, Webster MR, et\u00a0al. Age correlates with response to anti-PD1, reflecting age-related differences in intratumoral effector and regulatory T-cell populations. Clin Cancer Res. 2018;24:5347\u201356.","journal-title":"Clin Cancer Res"},{"key":"2928_CR28","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1097\/CMR.0b013e32832eabd5","volume":"19","author":"LV Kalialis","year":"2019","unstructured":"Kalialis LV, Drzewiecki KT, Klyver H. Spontaneous regression of metastases from melanoma: review of the literature. Melanoma Res. 2019;19:275\u201382.","journal-title":"Melanoma Res"},{"key":"2928_CR29","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s40425-018-0478-8","volume":"7","author":"O Mamlouk","year":"2019","unstructured":"Mamlouk O, Selamet U, Machado S, et\u00a0al. Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience. J Immunother Cancer. 2019;7:2.","journal-title":"J Immunother Cancer"},{"key":"2928_CR30","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12882-018-0848-y","volume":"19","author":"R Koda","year":"2018","unstructured":"Koda R, Watanabe H, Tsuchida M, et\u00a0al. Immune checkpoint inhibitor (nivolumab)-associated kidney injury and the importance of recognizing concomitant medications known to cause acute tubulointerstitial nephritis: a case report. BMC Nephrol. 2018;19:48.","journal-title":"BMC Nephrol"},{"key":"2928_CR31","first-page":"112","volume":"24","author":"H Backman","year":"1969","unstructured":"Backman H. Metastases of malignant melanoma in the gastrointestinal tract. Geriatrics. 1969;24:112\u201320.","journal-title":"Geriatrics"},{"key":"2928_CR32","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1002\/1097-0142(196410)17:10<1323::AID-CNCR2820171015>3.0.CO;2-N","volume":"17","author":"T Dasgupta","year":"1964","unstructured":"Dasgupta T, Brasfield R. Metastatic melanoma. a clinicopathological study. Cancer. 1964;17:1323\u201339.","journal-title":"Cancer"},{"key":"2928_CR33","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1097\/00004728-199107000-00008","volume":"15","author":"A Kawashima","year":"1991","unstructured":"Kawashima A, Fishman EK, Kuhlman JE, Schuchter LM. CT of malignant melanoma: patterns of small bowel and mesenteric involvement. J Comput Assist Tomogr. 1991;15:570\u20131.","journal-title":"J Comput Assist Tomogr"},{"key":"2928_CR34","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.ijsu.2014.02.011","volume":"12","author":"K Patel","year":"2014","unstructured":"Patel K, Ward ST, Packer T, et\u00a0al. Malignant melanoma of the gastro-intestinal tract: a case series. Int J Surg. 2014;12:523\u20137.","journal-title":"Int J Surg"},{"key":"2928_CR35","first-page":"712","volume":"88","author":"H Pomerantz","year":"1962","unstructured":"Pomerantz H, Margolin HN. Metastases to the gastrointestinal tract from malignant melanoma. Am J Roentgenol Radium Ther Nucl Med. 1962;88:712\u20137.","journal-title":"Am J Roentgenol Radium Ther Nucl Med"},{"key":"2928_CR36","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1111\/j.1440-1746.2011.06676.x","volume":"26","author":"PR Wu","year":"2011","unstructured":"Wu PR, Yen HH, Chen CJ. Gastrointestinal: primary esophageal melanoma with gastric metastasis. J Gastroenterol Hepatol. 2011;26:1338.","journal-title":"J Gastroenterol Hepatol"},{"key":"2928_CR37","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/7684964","author":"S Farshad","year":"2018","unstructured":"Farshad S, Keeney S, Halalau A, Ghaith G. A case of gastric metastatic melanoma 15 years after the initial diagnosis of cutaneous melanoma. Case Rep Gastrointest Med. 2018. https:\/\/doi.org\/10.1155\/2018\/7684964.","journal-title":"Case Rep Gastrointest Med"},{"key":"2928_CR38","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/2079068","author":"P Genova","year":"2017","unstructured":"Genova P, Sorce M, Cabibi D, et\u00a0al. Gastric and rectal metastases from malignant melanoma presenting with hypochromic anemia and treated with immunotherapy. Case Rep Oncol Med. 2017. https:\/\/doi.org\/10.1155\/2017\/2079068.","journal-title":"Case Rep Oncol Med"},{"key":"2928_CR39","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/S0302-2838(03)00416-0","volume":"44","author":"P Dahm","year":"2003","unstructured":"Dahm P, Gschwend JE. Malignant non-urothelial neoplasms of the urinary bladder: a review. Eur Urol. 2003;44:672\u201381.","journal-title":"Eur Urol"},{"key":"2928_CR40","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1046\/j.1365-2559.2000.00797.x","volume":"36","author":"AW Bates","year":"2000","unstructured":"Bates AW, Baithun SI. Secondary neoplasms of the bladder are histological mimics of nontransitional cell primary tumours: clinicopathological and histological features of 282 cases. Histopathology. 2000;36:32\u201340.","journal-title":"Histopathology"},{"key":"2928_CR41","first-page":"287","volume":"60","author":"GA Bumbu","year":"2019","unstructured":"Bumbu GA, Berechet MC, Pop OL, et\u00a0al. Primary malignant melanoma of the bladder\u2014case report and literature overview. Rom J Morphol Embryol. 2019;60:287\u201392.","journal-title":"Rom J Morphol Embryol"},{"key":"2928_CR42","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/173870","author":"R Meunier","year":"2015","unstructured":"Meunier R, Pareek G, Amin A. Metastasis of malignant melanoma to urinary bladder: a case report and review of the literature. Case Rep Pathol. 2015. https:\/\/doi.org\/10.1155\/2015\/173870.","journal-title":"Case Rep Pathol."},{"key":"2928_CR43","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-010-9730-x","author":"O Efesoy","year":"2011","unstructured":"Efesoy O, Cayan S. Bladder metastasis of malignant melanoma: a case report and review of literature. Med Oncol. 2011. https:\/\/doi.org\/10.1007\/s12032-010-9730-x.","journal-title":"Med Oncol"},{"key":"2928_CR44","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/916256","author":"S Charfi","year":"2012","unstructured":"Charfi S, Ellouze S, Mnif H, et\u00a0al. Plasmacytoid melanoma of the urinary bladder and lymph nodes with immunohistochemical expression of plasma cell markers revealing primary esophageal melanoma. Case Rep Pathol. 2012. https:\/\/doi.org\/10.1155\/2012\/916256.","journal-title":"Case Rep Pathol."},{"key":"2928_CR45","first-page":"787","volume":"54","author":"T Maeda","year":"2008","unstructured":"Maeda T, Uchida Y, Kouda T, et\u00a0al. Metastatic malignant melanoma of the urinary bladder presenting with hematuria: a case report. Acta Urol Jap. 2008;54:787\u201390 (in Japanese).","journal-title":"Acta Urol Jap."}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-021-02928-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13256-021-02928-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-021-02928-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,14]],"date-time":"2021-07-14T00:18:33Z","timestamp":1626221913000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-021-02928-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,14]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2928"],"URL":"https:\/\/doi.org\/10.1186\/s13256-021-02928-w","relation":{},"ISSN":["1752-1947"],"issn-type":[{"type":"electronic","value":"1752-1947"}],"subject":[],"published":{"date-parts":[[2021,7,14]]},"assertion":[{"value":"10 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"345"}}